BG
ALXN

Bellevue Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Bellevue Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-150
Closed -$113K – 227
2019
Q3 		$113K Buy
+150
New +$16.9K ﹤0.01% 210

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Bellevue Group's ALXN Position: Q3 2021 in Review

Bellevue Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 14,300 shares — an estimated $2.63M sold.

Bellevue Group first reported a position in ALXN in Q1 2016 and held it in 22 quarters. The position peaked at $218M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Bellevue Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Bellevue Group sold 14,300 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2.63M.
  • Bellevue Group first reported a position in Alexion Pharmaceuticals in Q1 2016 and held it in 22 quarters.
  • Bellevue Group's Alexion Pharmaceuticals position peaked at $218M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Bellevue Group's 13F filing for Q3 2021, filed 12 Nov 2021.